SPDR S&P Biotech ETF
552 hedge funds and large institutions have $8.95B invested in SPDR S&P Biotech ETF in 2020 Q3 according to their latest regulatory filings, with 91 funds opening new positions, 191 increasing their positions, 155 reducing their positions, and 57 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
4% less capital invested
Capital invested by funds: $9.36B → $8.95B (-$411M)
35% less funds holding in top 10
Funds holding in top 10: 17 → 11 (-6)
68% less call options, than puts
Call options by funds: $922M | Put options by funds: $2.85B
Holders
552
Holding in Top 10
11
Calls
$922M
Puts
$2.85B
Top Buyers
| 1 | +$439M | |
| 2 | +$111M | |
| 3 | +$77.1M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$58.8M |
| 5 |
Squarepoint
New York
|
+$28.2M |
Top Sellers
| 1 | -$450M | |
| 2 | -$343M | |
| 3 | -$123M | |
| 4 |
Barclays
London,
United Kingdom
|
-$68M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$53.9M |